Merck gets key approval on melanoma drug

Strauss, Eric
September 2014
njbiz;9/15/2014, Vol. 27 Issue 37, p3
The article reports that the U.S. Food and Drug Administration has approved drug manufacturer Merck's Keytruda (pembrolizumab) drug as treatment for patients with certain types of advanced melanoma as of mid-September 2014.


Related Articles

  • Pembrolizumab: First PD-1 blocking agent for advanced melanoma. ALDRIDGE YOUNG, CARA // Pharmacy Today;Nov2014, Vol. 20 Issue 11, p42 

    The article reports on the U.S. Food and Drug Administration's approval of the drug pembrolizumab for the treatment of patients with advanced or unresectable melanoma. The drug is a humanized monoclonal antibody, marketed as Keytruda and manufactured by Merck & Co. Information about the drug's...

  • Pembrolizumab. Khoja, Leila; Butler, Marcus O.; Kang, S. Peter; Ebbinghaus, Scot; Joshua, Anthony M. // Journal for ImmunoTherapy of Cancer;Aug2015, Vol. 3 Issue 1, p1 

    The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor...

  • Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma. Raedler, Lisa A. // Journal of Hematology Oncology Pharmacy;2016Specialissue, Vol. 6, p54 

    The article provides information approval of Imlygic (Talimogene Laherparepvec), an oncolytic viral therapy for treatment of Patients with Recurrent Melanoma, by U.S. Food and Drug Administration (FDA).

  • Specialty drug approvals: Review of 2014 and a forecast for 2015. CHANDANAIS, RYAN // Pharmacy Today;Jan2015, Vol. 21 Issue 1, p50 

    The article offers information on several specialty drugs approved by the U.S. Food and Drug Administration (FDA) in 2014, and includes forecast for 2015. Among the approved specialty drugs are Pembrolizumab for metastatic melanoma, sofosbuvir for Hepatitis C virus (HCV), and pirfenidone for...

  • CancerVax Treatment Goes Skin Deep. Webb, Marion // San Diego Business Journal;5/19/2003, Vol. 24 Issue 20, p1 

    Assesses the efficacy of Canvaxin drug in treating patients with melanoma disease. Approval of the U.S. Food and Administration on the distribution of the vaccine in the market; Risks of side effects; Forms of skin cancer.

  • FDA actions.  // Internal Medicine Alert;4/15/2011 Pharmacology Watch, p2 

    The article reports on the new drugs approved by the U.S. Food and Drug Administration including the vaccine Zostavax for the prevention of shingles, Ipilimumab for the treatment of late stage melanoma, and Belimumab for the treatment of systemic lupus erythematosus.

  • Vemurafenib Tablets (Zelborafâ„¢). Elliott, William T. // Internal Medicine Alert;10/29/2011, Vol. 33 Issue 20, p157 

    An abstract related to the U.S. Food and Drug Administration (FDA) review report conducted on the effectiveness of vemurafenib in patients with melanoma whose tumor expresses a gene mutation called BRAF V600E, is presented.

  • FDA approves Tafinlar, Mekinist for treatment of metastatic melanoma.  // Hem/Onc Today;6/25/2013, Vol. 14 Issue 12, p26 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of dabrafenib and trametinib for treatment of melanoma patients.

  • REMS accompanies launch of new melanoma drug.  // Reactions Weekly;4/16/2011, Issue 1347, p4 

    The article reports on the approval of Yervoy (ipilimumab) by the U.S. Food and Drug Administration (FDA) on March 26, 2011 for the treatment of unresectable or metastatic melanoma and the launching of a Risk Evaluation and Mitigation Strategy (REMS) by the drug's developer Bristol-Myers Squibb...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics